Hong Chen
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Hong Chen has a total of 83 co-authors. Here are the top co-authors by number of shared publications:
Shengxin Fan
Department of Pulmonary and Critical Care Medicine, the First Affiliated Hospital of Chongqing Medical University, Chongqing, China
3 shared publications- Xiaohui Wang
Department of Pulmonary and Critical Care Medicine, the First Affiliated Hospital of Chongqing Medical University, Chongqing, China
3 shared publications Xiaohui Wang
Department of Pulmonary and Critical Care Medicine, the First Affiliated Hospital of Chongqing Medical University, Chongqing, China
2 shared publicationsYuliang Liu
Department of Pulmonary and Critical Care Medicine, the First Affiliated Hospital of Chongqing Medical University, Chongqing, China
2 shared publications- Ahong Wang
Kashgar Prefecture Second Peoples Hosp, Dept Resp & Crit Care Med, Kashgar, Peoples R China
1 shared publication - Behnood Bikdeli
Heart and Vascular Institute, Brigham and Women’s Hospital , Mass General Brigham, Boston, MA
1 shared publication
Latest Publications
- Open Access
- 5 November 2026
- Published by BMJ in BMJ Open Respiratory Research
- Vol. 13 (1) , e004738
Effectiveness and major bleeding complications with venoarterial extracorporeal membrane oxygenation in category E pulmonary thromboembolism: a multicentre retrospective study
- 5 November 2026
- Published by BMJ in BMJ Open Respiratory Research
- Vol. 13 (1) , e004738
Open AccessEffectiveness and major bleeding complications with venoarterial extracorporeal membrane oxygenation in category E pulmonary thromboembolism: a multicentre retrospective study
- 28 October 2026
- Published by Oxford University Press (OUP) in European Heart Journal: Acute Cardiovascular Care
Prediction and Risk Stratification for 30-Day Mortality in Stable Acute Pulmonary Embolism: Recalibration of the Multimarker Calculator and Evaluation of the AHA/ACC Classification
Background: Risk stratification in haemodynamically stable acute pulmonary embolism (PE) remains challenging. The multimarker calculator (MMC) provides individualized 30-day mortality estimates, whereas the 2026 AHA/ACC Acute PE Clinical Categories (AHA/ACC classification) provide a phenotype-based framework incorporating clinical severity, right ventricular dysfunction, cardiac biomarker elevation, and respiratory compromise. We evaluated these approaches and recalibrated the original MMC in a Chinese multicentre cohort. Methods: We included adults with haemodynamically stable acute PE from the prospective, multicentre China pUlmonary thromboembolism REgistry Study (2012–2021). The primary outcome was 30-day all-cause mortality. The MMC, 2019 European Society of Cardiology (ESC) model, and AHA/ACC classification were assessed using discrimination, decision-curve analysis, risk classification, and subgroup analyses. Logistic recalibration updated the original MMC linear predictor. The AHA/ACC classification was evaluated using 7-, 4-, and simplified phenotype-based 3-category schemes. Results: Among 11,568 patients, 331 died within 30 days (2.9%). The MMC and 7-category AHA/ACC classification showed better discrimination than the ESC model (AUC, 0.704 and 0.680 vs. 0.606). The original MMC overestimated intermediate-high-risk mortality (mean predicted risk, 16.2%; observed risk, 9.4%). Recalibration improved calibration and identified a smaller intermediate-high-risk subgroup comprising 2.2% of patients, with 13.2% observed mortality. In the 3-category AHA/ACC classification, mortality increased stepwise across category B, partial phenotype involvement, and dual cardiopulmonary phenotype involvement (0.7%, 2.7%, and 6.7%). Conclusions: The recalibrated MMC may be useful for individualized 30-day mortality risk estimation, whereas the AHA/ACC classification may offer a simple framework for phenotype-based risk grouping.
- 28 October 2026
- Published by Oxford University Press (OUP) in European Heart Journal: Acute Cardiovascular Care
Prediction and Risk Stratification for 30-Day Mortality in Stable Acute Pulmonary Embolism: Recalibration of the Multimarker Calculator and Evaluation of the AHA/ACC Classification
Background: Risk stratification in haemodynamically stable acute pulmonary embolism (PE) remains challenging. The multimarker calculator (MMC) provides individualized 30-day mortality estimates, whereas the 2026 AHA/ACC Acute PE Clinical Categories (AHA/ACC classification) provide a phenotype-based framework incorporating clinical severity, right ventricular dysfunction, cardiac biomarker elevation, and respiratory compromise. We evaluated these approaches and recalibrated the original MMC in a Chinese multicentre cohort. Methods: We included adults with haemodynamically stable acute PE from the prospective, multicentre China pUlmonary thromboembolism REgistry Study (2012–2021). The primary outcome was 30-day all-cause mortality. The MMC, 2019 European Society of Cardiology (ESC) model, and AHA/ACC classification were assessed using discrimination, decision-curve analysis, risk classification, and subgroup analyses. Logistic recalibration updated the original MMC linear predictor. The AHA/ACC classification was evaluated using 7-, 4-, and simplified phenotype-based 3-category schemes. Results: Among 11,568 patients, 331 died within 30 days (2.9%). The MMC and 7-category AHA/ACC classification showed better discrimination than the ESC model (AUC, 0.704 and 0.680 vs. 0.606). The original MMC overestimated intermediate-high-risk mortality (mean predicted risk, 16.2%; observed risk, 9.4%). Recalibration improved calibration and identified a smaller intermediate-high-risk subgroup comprising 2.2% of patients, with 13.2% observed mortality. In the 3-category AHA/ACC classification, mortality increased stepwise across category B, partial phenotype involvement, and dual cardiopulmonary phenotype involvement (0.7%, 2.7%, and 6.7%). Conclusions: The recalibrated MMC may be useful for individualized 30-day mortality risk estimation, whereas the AHA/ACC classification may offer a simple framework for phenotype-based risk grouping.
- Open Access
- 1 September 2025
- Published by Springer Nature in BMC Cardiovascular Disorders
- Vol. 25 (1) , 1-12
Anticoagulation in critically ill patients with isolated distal deep vein thrombosis: a retrospective cohort study
Anticoagulation for isolated distal deep vein thrombosis (IDDVT) in critically ill patients remains controversial. The aim of our study was to assess whether anticoagulation could benefit critically ill patients with IDDVT. We identified critically ill patients with IDDVT diagnosed by ultrasound from June 2022 to June 2023 and divided them into anticoagulation and non-anticoagulation groups retrospectively. The primary outcome was thrombus propagation, defined as a composite of pulmonary embolism (PE) and proximal deep vein thrombosis (PDVT). The secondary outcomes included PE, PDVT, thrombus resolution, major bleeding, clinically relevant non-major bleeding and all-cause mortality. The follow-up period was from the day of IDDVT diagnosis to the time of discharge/death. After propensity score matching (PSM), the incidence of outcomes was compared and risk factors for thrombus propagation/bleeding were analyzed. A total of 261 patients were included for analysis, 115 in the non-anticoagulation group and 146 in the anticoagulation group. After PSM, 53 pairs of patients were well-matched. The incidence of thrombus propagation was significantly lower in the anticoagulation group than in the non-anticoagulation group (5.7% vs. 18.9%, P = 0.038). However, there was no statistical difference in the incidence of secondary outcomes between the two groups. Subgroup analysis revealed that over 70% of patients received low-dose rather than standard-dose anticoagulation, particularly those with coagulopathy and deep vein catheterization, and no significant differences were observed in any outcomes between the two subgroups. Finally, surgery (OR 3.959, 95% CI 1.101–14.233, P = 0.035) was an independent risk factor for thrombus propagation, while early anticoagulation (OR 0.243, 95% CI 0.061–0.966, P = 0.045) was a protective factor. Active malignant tumor (OR 10.257, 95% CI 1.883–55.870, P = 0.007), trauma (OR 9.766, 95% CI 1.193–79.948, P = 0.034), and an IMPROVE score ≥ 7 (OR 5.279, 95% CI 1.146–24.321, P = 0.033) were all independent risk factors for bleeding. Early low-dose anticoagulation can reduce the risk of thrombus propagation in critically ill patients with IDDVT without increasing bleeding risk, but caution should be exercised in those with active malignant tumor, trauma or an IMPROVE score ≥ 7, given their inherently high bleeding risk.
- 1 September 2025
- Published by Springer Nature in BMC Cardiovascular Disorders
- Vol. 25 (1) , 1-12
Open AccessAnticoagulation in critically ill patients with isolated distal deep vein thrombosis: a retrospective cohort study
Anticoagulation for isolated distal deep vein thrombosis (IDDVT) in critically ill patients remains controversial. The aim of our study was to assess whether anticoagulation could benefit critically ill patients with IDDVT. We identified critically ill patients with IDDVT diagnosed by ultrasound from June 2022 to June 2023 and divided them into anticoagulation and non-anticoagulation groups retrospectively. The primary outcome was thrombus propagation, defined as a composite of pulmonary embolism (PE) and proximal deep vein thrombosis (PDVT). The secondary outcomes included PE, PDVT, thrombus resolution, major bleeding, clinically relevant non-major bleeding and all-cause mortality. The follow-up period was from the day of IDDVT diagnosis to the time of discharge/death. After propensity score matching (PSM), the incidence of outcomes was compared and risk factors for thrombus propagation/bleeding were analyzed. A total of 261 patients were included for analysis, 115 in the non-anticoagulation group and 146 in the anticoagulation group. After PSM, 53 pairs of patients were well-matched. The incidence of thrombus propagation was significantly lower in the anticoagulation group than in the non-anticoagulation group (5.7% vs. 18.9%, P = 0.038). However, there was no statistical difference in the incidence of secondary outcomes between the two groups. Subgroup analysis revealed that over 70% of patients received low-dose rather than standard-dose anticoagulation, particularly those with coagulopathy and deep vein catheterization, and no significant differences were observed in any outcomes between the two subgroups. Finally, surgery (OR 3.959, 95% CI 1.101–14.233, P = 0.035) was an independent risk factor for thrombus propagation, while early anticoagulation (OR 0.243, 95% CI 0.061–0.966, P = 0.045) was a protective factor. Active malignant tumor (OR 10.257, 95% CI 1.883–55.870, P = 0.007), trauma (OR 9.766, 95% CI 1.193–79.948, P = 0.034), and an IMPROVE score ≥ 7 (OR 5.279, 95% CI 1.146–24.321, P = 0.033) were all independent risk factors for bleeding. Early low-dose anticoagulation can reduce the risk of thrombus propagation in critically ill patients with IDDVT without increasing bleeding risk, but caution should be exercised in those with active malignant tumor, trauma or an IMPROVE score ≥ 7, given their inherently high bleeding risk.
- Open Access
- 13 April 2025
- Published by SAGE Publications in Clinical and Applied Thrombosis/Hemostasis
- Vol. 31
The Standardized Prophylaxis and Risk Factors for Venous Thromboembolism in Patients of Respiratory Intensive Care Unit: A Retrospective Observational Study
Background: Critically ill patients in intensive care unit (ICU) are at high risk of venous thromboembolism (VTE). The standardized prophylaxis of VTE in these patients and the appropriate prevention protocols are not very clear. Method: We enrolled 426 patients admitted to respiratory intensive care unit (RICU), all of them underwent Padua risk scoring and patients at high risk of VTE also underwent bleeding risk scoring. We compared the VTE prevention methods that followed the guidelines between two different bleeding risk groups and the VTE incidence of these two groups. We also analyzed the risk factors for VTE in RICU patients. Results: In patients admitted to RICU, the rate of overall VTE prophylaxis was 71.3% (295/414), but the rate of standardized prophylaxis of VTE was only 32.6% (135/414). The standardized prophylaxis rate of VTE in high-risk bleeding patients was 40.3%, much higher than the 22.2% in low-risk bleeding patients ( P < 0.001). There was also a significant difference in the incidence of VTE between the two groups (26.9%vs3.4%, P < 0.001). 70 (16.9%) patients in RICU developed VTE, the multivariable logistic regression analysis showed that immobilization time, pulmonary encephalopathy, oral or inject corticosteroids, trauma or surgery within 3 months were independent risk factors of VTE in patients admitted to RICU, while pharmacological prophylaxis was a protective factor for VTE. The receiver operating characteristic (ROC) curve showed that the above composite indicators had a higher predictive value for RICU patients with VTE, with a ROC area under the curve (AUC) of 0.925 (95%CI 0.894–0.956, P < 0.001). Conclusion: Although the overall prophylaxis rate of VTE in patients admitted to RICU was high, the rate of standardized prevention was not ideal. Pharmacological prophylaxis may play an important role in preventing VTE in RICU patients and fruther studies are needed to explore the optimal thromboprophylaxis protocol for critically ill patients.
- 13 April 2025
- Published by SAGE Publications in Clinical and Applied Thrombosis/Hemostasis
- Vol. 31
Open AccessThe Standardized Prophylaxis and Risk Factors for Venous Thromboembolism in Patients of Respiratory Intensive Care Unit: A Retrospective Observational Study
Background: Critically ill patients in intensive care unit (ICU) are at high risk of venous thromboembolism (VTE). The standardized prophylaxis of VTE in these patients and the appropriate prevention protocols are not very clear. Method: We enrolled 426 patients admitted to respiratory intensive care unit (RICU), all of them underwent Padua risk scoring and patients at high risk of VTE also underwent bleeding risk scoring. We compared the VTE prevention methods that followed the guidelines between two different bleeding risk groups and the VTE incidence of these two groups. We also analyzed the risk factors for VTE in RICU patients. Results: In patients admitted to RICU, the rate of overall VTE prophylaxis was 71.3% (295/414), but the rate of standardized prophylaxis of VTE was only 32.6% (135/414). The standardized prophylaxis rate of VTE in high-risk bleeding patients was 40.3%, much higher than the 22.2% in low-risk bleeding patients ( P < 0.001). There was also a significant difference in the incidence of VTE between the two groups (26.9%vs3.4%, P < 0.001). 70 (16.9%) patients in RICU developed VTE, the multivariable logistic regression analysis showed that immobilization time, pulmonary encephalopathy, oral or inject corticosteroids, trauma or surgery within 3 months were independent risk factors of VTE in patients admitted to RICU, while pharmacological prophylaxis was a protective factor for VTE. The receiver operating characteristic (ROC) curve showed that the above composite indicators had a higher predictive value for RICU patients with VTE, with a ROC area under the curve (AUC) of 0.925 (95%CI 0.894–0.956, P < 0.001). Conclusion: Although the overall prophylaxis rate of VTE in patients admitted to RICU was high, the rate of standardized prevention was not ideal. Pharmacological prophylaxis may play an important role in preventing VTE in RICU patients and fruther studies are needed to explore the optimal thromboprophylaxis protocol for critically ill patients.
- Open Access
- 30 August 2024
- Published by Springer Nature in BMC Pulmonary Medicine
- Vol. 24 (1) , 1-17
Bronchial artery embolization versus conservative treatment for hemoptysis: a systematic review and meta-analysis
Bronchial artery embolization (BAE) is currently an important treatment for hemoptysis. However, there is no consensus in the efficacy and safety of BAE compared to conservative treatment for hemoptysis, which limits the widespread use of BAE in hemoptysis. The objective was to assess the clinical benefit of BAE versus conservative treatment in patients with hemoptysis. A systematic search was conducted on the PubMed, Embase, ScienceDirect, CochraneLibrary, and ClinicalTrials up to March 2023. Both randomized controlled trials (RCTs) and cohort studies reporting rates of recurrent hemoptysis, clinical success, mortality, and complication by BAE and conservative treatment alone for hemoptysis were included. Data were pooled and compared by the use of odds ratio (OR) and 95% confidence interval (CI). Twelve studies (three RCTs, nine cohorts) involving 1231 patients met the eligibility criteria. Patients treated with BAE had lower recurrence rates of hemoptysis (26.5% vs. 34.6%; OR 0.37, 95% CI 0.14–0.98), higher clinical success rates (92.2% vs. 80.9%; OR 2.77, 95% CI 1.66–4.61), and lower hemoptysis-related mortality (0.8% vs. 3.2%; OR 0.20, 95% CI 0.05–0.84) compared with conservative treatment alone. There was no significant difference in all-cause mortality between the two groups. In terms of security, the incidence of major complications and minor complications in patients undergoing BAE treatment was 0.2% (1/422) and 15.6%, respectively. BAE was more effective than conservative treatment alone in controlling hemoptysis, reducing recurrence, and decreasing hemoptysis-related mortality, with an almost negligible risk of major complications.
- 30 August 2024
- Published by Springer Nature in BMC Pulmonary Medicine
- Vol. 24 (1) , 1-17
Open AccessBronchial artery embolization versus conservative treatment for hemoptysis: a systematic review and meta-analysis
Bronchial artery embolization (BAE) is currently an important treatment for hemoptysis. However, there is no consensus in the efficacy and safety of BAE compared to conservative treatment for hemoptysis, which limits the widespread use of BAE in hemoptysis. The objective was to assess the clinical benefit of BAE versus conservative treatment in patients with hemoptysis. A systematic search was conducted on the PubMed, Embase, ScienceDirect, CochraneLibrary, and ClinicalTrials up to March 2023. Both randomized controlled trials (RCTs) and cohort studies reporting rates of recurrent hemoptysis, clinical success, mortality, and complication by BAE and conservative treatment alone for hemoptysis were included. Data were pooled and compared by the use of odds ratio (OR) and 95% confidence interval (CI). Twelve studies (three RCTs, nine cohorts) involving 1231 patients met the eligibility criteria. Patients treated with BAE had lower recurrence rates of hemoptysis (26.5% vs. 34.6%; OR 0.37, 95% CI 0.14–0.98), higher clinical success rates (92.2% vs. 80.9%; OR 2.77, 95% CI 1.66–4.61), and lower hemoptysis-related mortality (0.8% vs. 3.2%; OR 0.20, 95% CI 0.05–0.84) compared with conservative treatment alone. There was no significant difference in all-cause mortality between the two groups. In terms of security, the incidence of major complications and minor complications in patients undergoing BAE treatment was 0.2% (1/422) and 15.6%, respectively. BAE was more effective than conservative treatment alone in controlling hemoptysis, reducing recurrence, and decreasing hemoptysis-related mortality, with an almost negligible risk of major complications.
- Open Access
- 21 January 2023
- Published by European Publishing in Tobacco Induced Diseases
- Vol. 21 (January) , 1-13
Usage, acceptability, and preliminary effectiveness of an mHealth-based integrated modality for smoking cessation interventions in Western China
Introduction: Many smokers have not accessed professional smoking cessation assistance due to limited smoking cessation services. We developed a novel mHealth-based integrated modality for smoking cessation (WeChat + Quitline modality, WQ modality) and applied it to a large public welfare...
- 21 January 2023
- Published by European Publishing in Tobacco Induced Diseases
- Vol. 21 (January) , 1-13
Open AccessUsage, acceptability, and preliminary effectiveness of an mHealth-based integrated modality for smoking cessation interventions in Western China
Introduction: Many smokers have not accessed professional smoking cessation assistance due to limited smoking cessation services. We developed a novel mHealth-based integrated modality for smoking cessation (WeChat + Quitline modality, WQ modality) and applied it to a large public welfare...
- Open Access
- 27 November 2021
- Published by Springer Nature in Thrombosis Journal
- Vol. 19 (1) , 1-11
Patients with venous thromboembolism after spontaneous intracerebral hemorrhage: a review
Background: Patients with spontaneous intracerebral hemorrhage (ICH) have a higher risk of venous thromboembolism (VTE) and in-hospital VTE is independently associated with poor outcomes for this patient population. Methods: A comprehensive literature search about patients with VTE after spontaneous ICH was conducted using databases MEDLINE and PubMed. We searched for the following terms and other related terms (in US and UK spelling) to identify relevant studies: intracerebral hemorrhage, ICH, intraparenchymal hemorrhage, IPH, venous thromboembolism, VTE, deep vein thrombosis, DVT, pulmonary embolism, and PE. The search was restricted to human subjects and limited to articles published in English. Abstracts were screened and data from potentially relevant articles was analyzed. Results: The prophylaxis and treatment of VTE are of vital importance for patients with spontaneous ICH. Prophylaxis measures can be mainly categorized into mechanical prophylaxis and chemoprophylaxis. Treatment strategies include anticoagulation, vena cava filter, systemic thrombolytic therapy, catheter-based thrombus removal, and surgical embolectomy. We briefly summarized the state of knowledge regarding the prophylaxis measures and treatment strategies of VTE after spontaneous ICH in this review, especially on chemoprophylaxis and anticoagulation therapy. Early mechanical prophylaxis, especially with intermittent pneumatic compression, is recommended by recent guidelines for patients with spontaneous ICH. While decision-making on chemoprophylaxis and anticoagulation therapy evokes debate among clinicians, because of the concern that anticoagulants may increase the risk of recurrent ICH and hematoma expansion. Uncertainty still exists regarding optimal anticoagulants, the timing of initiation, and dosage. Conclusion: Based on current evidence, we deem that initiating chemoprophylaxis with UFH/LMWH within 24–48 h of ICH onset could be safe; anticoagulation therapy should depend on individual clinical condition; the role of NOACs in this patient population could be promising.
- 27 November 2021
- Published by Springer Nature in Thrombosis Journal
- Vol. 19 (1) , 1-11
Open AccessPatients with venous thromboembolism after spontaneous intracerebral hemorrhage: a review
Background: Patients with spontaneous intracerebral hemorrhage (ICH) have a higher risk of venous thromboembolism (VTE) and in-hospital VTE is independently associated with poor outcomes for this patient population. Methods: A comprehensive literature search about patients with VTE after spontaneous ICH was conducted using databases MEDLINE and PubMed. We searched for the following terms and other related terms (in US and UK spelling) to identify relevant studies: intracerebral hemorrhage, ICH, intraparenchymal hemorrhage, IPH, venous thromboembolism, VTE, deep vein thrombosis, DVT, pulmonary embolism, and PE. The search was restricted to human subjects and limited to articles published in English. Abstracts were screened and data from potentially relevant articles was analyzed. Results: The prophylaxis and treatment of VTE are of vital importance for patients with spontaneous ICH. Prophylaxis measures can be mainly categorized into mechanical prophylaxis and chemoprophylaxis. Treatment strategies include anticoagulation, vena cava filter, systemic thrombolytic therapy, catheter-based thrombus removal, and surgical embolectomy. We briefly summarized the state of knowledge regarding the prophylaxis measures and treatment strategies of VTE after spontaneous ICH in this review, especially on chemoprophylaxis and anticoagulation therapy. Early mechanical prophylaxis, especially with intermittent pneumatic compression, is recommended by recent guidelines for patients with spontaneous ICH. While decision-making on chemoprophylaxis and anticoagulation therapy evokes debate among clinicians, because of the concern that anticoagulants may increase the risk of recurrent ICH and hematoma expansion. Uncertainty still exists regarding optimal anticoagulants, the timing of initiation, and dosage. Conclusion: Based on current evidence, we deem that initiating chemoprophylaxis with UFH/LMWH within 24–48 h of ICH onset could be safe; anticoagulation therapy should depend on individual clinical condition; the role of NOACs in this patient population could be promising.
- 5 March 2021
- Published by Springer Nature in Journal of Thrombosis and Thrombolysis
- Vol. 52 (3) , 863-871
Current use of rivaroxaban in elderly patients with venous thromboembolism (VTE)
Venous thromboembolism (VTE), which is characterized by pulmonary embolism and deep vein thrombosis, has become a serious public concern. Notably, over half of the patients with VTE are over 70 years of age, but elderly patients are at high risk of anti-coagulation and bleeding, which increase with age. Moreover, risk factors and frailty also show a difference between elderly patients and ordinary patients diagnosed with VTE. Rivaroxaban is a direct inhibitor of activated factor Xa and has the advantage of predictable pharmacodynamics and pharmacokinetics, no coagulation monitoring, and few drug interactions. As a first-line therapy for VTE, this drug is more advantageous than traditional therapy and exhibits good efficacy and safety for ordinary patients. However, the effectiveness and safety of rivaroxaban in elderly patients have not been fully elucidated. This article reviewed the use of rivaroxaban in elderly patients, including drug interactions, monitoring, reversal agents of rivaroxaban, and the use of small dosages of rivaroxaban in elderly patients.
- 5 March 2021
- Published by Springer Nature in Journal of Thrombosis and Thrombolysis
- Vol. 52 (3) , 863-871
Current use of rivaroxaban in elderly patients with venous thromboembolism (VTE)
Venous thromboembolism (VTE), which is characterized by pulmonary embolism and deep vein thrombosis, has become a serious public concern. Notably, over half of the patients with VTE are over 70 years of age, but elderly patients are at high risk of anti-coagulation and bleeding, which increase with age. Moreover, risk factors and frailty also show a difference between elderly patients and ordinary patients diagnosed with VTE. Rivaroxaban is a direct inhibitor of activated factor Xa and has the advantage of predictable pharmacodynamics and pharmacokinetics, no coagulation monitoring, and few drug interactions. As a first-line therapy for VTE, this drug is more advantageous than traditional therapy and exhibits good efficacy and safety for ordinary patients. However, the effectiveness and safety of rivaroxaban in elderly patients have not been fully elucidated. This article reviewed the use of rivaroxaban in elderly patients, including drug interactions, monitoring, reversal agents of rivaroxaban, and the use of small dosages of rivaroxaban in elderly patients.
- 1 September 2020
- Published by International Union Against Tuberculosis and Lung Disease in The International Journal of Tuberculosis and Lung Disease
- Vol. 24 (9) , 941-947
Change in smoking behaviour of people who suffer from respiratory disease
OBJECTIVE: To analyse smoking behaviour in patients suffering from non-small cell lung cancer (NSCLC), chronic obstructive pulmonary disease (COPD) and pulmonary TB (PTB). METHODS: The study population comprised 421 inpatients newly diagnosed with NSCLC, COPD and PTB at the First Affiliated Hospital of Chongqing Medical University, Chongqing, China, and 362 healthy individuals (controls) recruited from September 2016 to March 2017. All participants were current smokers. After enrolment, the subjects were invited to participate in face-to-face interviews to complete the self-designed questionnaire. A follow-up survey was performed 2 years later. RESULTS: Two years after being diagnosed, patients with NSCLC, COPD and PTB had smoking cessation rates of respectively 76.8%, 62.8% and 63.7%. The cessation rate was only 10.2% in the control group (P < 0.01). The difficulty of smoking cessation after diagnosis in patients with the three diseases was significantly decreased (P < 0.01). CONCLUSION: The smoking cessation rate among participants suffering from NSCLC, COPD and PTB increased after diagnosis compared with that before diagnosis, and was significantly higher than the control group of healthy individuals.
- 1 September 2020
- Published by International Union Against Tuberculosis and Lung Disease in The International Journal of Tuberculosis and Lung Disease
- Vol. 24 (9) , 941-947
Change in smoking behaviour of people who suffer from respiratory disease
OBJECTIVE: To analyse smoking behaviour in patients suffering from non-small cell lung cancer (NSCLC), chronic obstructive pulmonary disease (COPD) and pulmonary TB (PTB). METHODS: The study population comprised 421 inpatients newly diagnosed with NSCLC, COPD and PTB at the First Affiliated Hospital of Chongqing Medical University, Chongqing, China, and 362 healthy individuals (controls) recruited from September 2016 to March 2017. All participants were current smokers. After enrolment, the subjects were invited to participate in face-to-face interviews to complete the self-designed questionnaire. A follow-up survey was performed 2 years later. RESULTS: Two years after being diagnosed, patients with NSCLC, COPD and PTB had smoking cessation rates of respectively 76.8%, 62.8% and 63.7%. The cessation rate was only 10.2% in the control group (P < 0.01). The difficulty of smoking cessation after diagnosis in patients with the three diseases was significantly decreased (P < 0.01). CONCLUSION: The smoking cessation rate among participants suffering from NSCLC, COPD and PTB increased after diagnosis compared with that before diagnosis, and was significantly higher than the control group of healthy individuals.